Skip to main content

Table 1 Patient and treatment characteristics (N = 159 patients)

From: Association of pre-chemotherapy peripheral blood pro-inflammatory and coagulation factors with reduced relative dose intensity in women with breast cancer

Baseline characteristics   
Age, years 59.0 30–81
Age group, years
  < 50 38 23.9%
 50 to < 60 44 27.5%
 60 to < 70 46 28.8%
  ≥ 70 31 19.4%
Race
 Non-Hispanic white 80 50.3%
 Hispanic 40 25.2%
 African-American 17 10.7%
 Asian 15 9.4%
 Others 6 3.8%
 Missing data 1 0.6%
Breast cancer stage
 I 34 21.4%
 II 88 55.3%
 III 37 23.3%
ER, PR, HER2 status
 ER+ or PR+, HER2- 106 66.7%
 HER2+ 25 15.7%
 ER-PR-HER2- 28 17.6%
Type of chemotherapy
 Neoadjuvant 17 10.7%
 Adjuvant 142 89.3%
Chemotherapy regimen
 AC-T 56 35.2%
 TC 59 37.1%
 AC-TH 11 6.9%
 TCH 11 6.9%
 Sequential A-T-C 10 6.3%
 Other non-HER2-targeted therapy 6 3.8%
 Other HER-2-targeted therapy 6 3.8%
Anthracycline-containing regimen
 No 75 47.2%
 Yes 84 52.8%
Comorbidities
 Hypertension 54 34.0%
 Arthritis 47 29.6%
 Depression 31 19.5%
 Circulation problem 22 13.8%
 Other cancers 18 11.3%
 Stomach disorders 17 10.7%
Othera
 Number of comorbidities ≥ 1 105 66.0%
 Number of comorbidities ≥ 2 64 40.3%
 Number of comorbidities ≥ 3 35 22.0%
  1. Values are presented as median and range, or number and percentage
  2. ER estrogen receptor, PR progesterone receptor, HER2 human epidermal growth factor receptor 2, TC docetaxel plus cyclophosphamide, AC-T doxorubicin plus cyclophosphamide followed by paclitaxel, TCH docetaxel, carboplatin and trastuzumab, AC-TH doxorubicin plus cyclophosphamide followed by paclitaxel plus trastuzumab, A-T-C sequential doxorubicin, paclitaxel and cyclophosphamide
  3. aOther: heart disease (N = 15, 9.4%); diabetes mellitus (N =12, 7.5%); glaucoma (N = 9, 5.7%); emphysema (N = 5, 3.1%); liver/kidney disease (N = 2, 1.3%); stroke (N = 1, 0.6%)